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As disease concepts have changed, the treatment of idiopathic interstitial pneumonias
(IIPs) has become focused on idiopathic pulmonary ﬁbrosis (IPF), which has the most
adverse prognosis. Since 1998, large-scale multicenter trials have evolved, and clinical
trials using novel therapeutic drugs such as interferon-g in US and N-acetylcysteine in
Europe and pirfenidone in Japan, have been organized. Most of these trials were evaluated
using 1-year FVC or VC changes as the therapy endpoint, with signiﬁcant differences
obtained for non-progressive stage IPF. However, no signiﬁcant differences were obtained
in the progressive stages for any of the trials, and whether or not they contribute to
improvement in life prognosis has been left to the post-market evaluation. A debate has
begun in Europe and the US as to the value of assessment evaluation indicator done during
activity since constant speed treadmill walking tests were introduced in the pirfenidone
clinical trials carried out in Japan. Until now, therapy evaluations for IIPs have been
compared using diagnostic imaging, pulmonary function tests, and pathology. In the
future, therapeutic efﬁcacy and prognosis will be discussed in terms not only of resting
respiratory function evaluation, but also of systemic evaluation using exercise endurance,
which is also recognized as an ADL evaluation indicator. In recent years, acute
exacerbation of IPF has been the focus of global concern. A joint perspective by ATS/
ERS was published, and standardized diagnosis and treatment have been provided. Acute
exacerbation is an adverse prognosis factor, as are lung cancer complications, and
treatments for improving life prognosis are being explored. This paper presents
therapeutic drugs and treatments whose introduction is awaited, and discusses the
relationship between indicators of therapy evaluation and disease concepts.
& 2008 Elsevier Ltd. All rights reserved.Educational aims: To review the therapy for Idiopathic Pulmonary Fibrosis.
 To familiarize the reader with how to Evaluate the Efﬁcacy.Elsevier Ltd. All rights reserved.
p (A. Azuma). To look at drug trials which have been carried out in Japan.
Introduction
Idiopathic interstitial pneumonia (IIP) is the generic name
for the rare group of diseases constituting interstitial
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Table 1 Effect of IFN-g1b treatment in total three
study.
Period Hazard
ratio
95% CI p
All 0.418 0.253–0.690 0.0003
1 yr 0.0861 0.0244–0.1478 0.0063
1.5 yr 0.1682 0.1065–0.2299 o0.0001
1.78 yr 0.1939 0.1386–0.2494 o0.0001
2 yr 0.2652 0.1652–0.3652 o0.0001
n ¼ 390, reduced mortality. Post-analysis synthesis of inter-
feron-g therapy trial.9 The possibility of contribution to
lowering the long-term mortality ratio is indicated.
A. Azuma, J. Usuki76pneumonias of unknown etiology. Currently they are
classiﬁed into seven different patho-morphologies. In Japan
they are recognized as intractable diseases and 4400 cases
have been registered (to quality for medical care subsidy,
severity of PaO2o70 Torr in resting state or SpO2o90% after
6-min walking).1 In the US, the number of affected
individuals estimated is 83,000. Among these, idiopathic
pulmonary ﬁbrosis (IPF) is chronic and progressive, and most
resistant to treatment.2 Therefore, a continuous stream of
novel therapeutic drug clinical trials are being carried out in
response to the continued demand for IPF therapeutic drug
development. Since 1994, when nonspeciﬁc interstitial
pneumonia (NSIP) was excluded as a separate disease
concept,3 IPF has been seen as a treatment-resistant
interstitial pneumonia. Nevertheless, based upon pathologic
recognition of the inﬂammation as pre-existing, compara-
tively small-scale clinical trials have been developed
according to treatment concepts focusing on immune
suppression. After reporting hopeful results from interfer-
on-g clinical trials,4 several large-scale multicenter trials
have been funded. However, due to the variability of the
disease trajectory across individuals and the lack of
established gold standard of success, the main endpoints
for each trial differs and thus efﬁcacy results also differ.
Unfortunately, no drug has demonstrated improvement in
survival, which is the desired absolute indicator of success.
If there is no outcome of improved survival, issues have been
raised regarding the evaluation measures of pirfenidone,
which has been developed and tested in Japan. In that
context, this paper assesses the future prospects of novel
drug development, focusing on global IPF clinical trials.Progression of novel therapies for IPF
Clinical trials of interferon-c
With regard to interferon-g, which appeared to great
fanfare after small-scale randomized unblinded trial results4
were reported in 1999, a large-scale randomized double
blind multicenter clinical trial was carried out in North
America on 330 IPF patients. The results showed no
signiﬁcant difference between those cases and the placebo
group when comparing the main intent-to-treat (ITT) end-
point, ‘‘progression free survival interval’’.5 However, an
improved prognosis was suggested in non-advanced cases
where %VC455%. Meanwhile, in clinical trials carried out on
IPF cases in the progressive stage, respiratory function
deterioration was prevented in none of the cases,6,7 and
there were reports of conﬁrmed exacerbated pathology
accompanying IFNg therapy.8 However, a synthesis of post-
analyses of randomized IFNg therapy results suggests the
possibility of its contribution to mortality ratio reduction
over the long-term prognosis9 (Table 1).
Based on these lessons, late phase III clinical trials on non-
advanced cases were planned and carried out in Europe and
the US, with a trial period of 2 years and target case number
of more than 800 IPF patients and ‘‘survival ratio’’ as main
endpoint. In particular, the trial design entailed non-
progressive cases with 90%4FVC455%, and 90%4DLco/
TLC435%.10 However, the results published in March 2007
reported it as a ‘‘negative study.’’ The main endpoint waschanged, but ultimately the efﬁcacy of interferon-g was
rejected.11European trial of N-acetylcysteine (NAC)
There is anoxidant/antioxidant imbalance in the lungs of IPF
patients, and glutathione is low in the bronchoalveolar
lavage ﬂuid (BALF).12 The clinical efﬁcacy of high-dose
orally administered NAC for IPF patients was reported from
Europe in 1997. Its antioxidant effect on interstitial
pneumonia was noted, resulting in a pilot clinical study
where NAC was administered orally 600mg three times a day
for 12 weeks.13 The results showed that plasma total
glutathione increased slightly from before to after NAC
therapy, while BAL and epithelial lining ﬂuid total glu-
tathione increased demonstrably from before to after NAC
therapy. Auscultatory ﬁndings conﬁrmed a 22% reduction in
crackle intensity and distribution, while breathing difﬁculty
improved by 50%. Results of the respiratory function
continue to decline during the pre-treatment observation
period, with improvement seen after the 12-week NAC
therapy. Based on the above results, it was reported that
high-dose NAC oral therapy was an effective adjunctive
therapy for IPF patients.
At the 2004 European Respiratory Society (ERS) meeting,
a randomized clinical trial with prednisolone (progressive
reduction starting from 0.5mg/kg/day) and azathioprine
(2mg/kg/day) as the intervention arm therapy.
Overall, 184 IPF patients (155 cases available for ﬁnal
analysis) were divided into the NAC (internal dose of
1800mg/day) and placebo groups and compared. After 12
months, VC and DLco showed less reduction among the
intervention group14 (Figure 1). However, survival was not
improved.
In Japan, NAC, as a precursor of glutathione, is used as an
inhaled expectorant drug for bronchial asthma and chronic
bronchitis, with expectations of preventive effects for
pulmonary damage caused by oxidants.
A pilot trial on NAC inhalation therapy for IPF was
reported by a Ministry of Health and Welfare study group.15
Since 2005, physician-led multicenter research (part of
‘‘Clinical Research on Landmark Therapy for Idiopathic
Interstitial Pneumonias’’ by a Ministry of Health and Welfare
study group) has been carried out as the ﬁrst publicly
ﬁnanced clinical trial in Japan, and we await the results.
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Figure 1 IFIGENIA trial results. Compared to the placebo group, all deterioration indicators (VC, DLco, VC% and DLco%) were
alleviated in the NAC therapy group.14.
Novel therapy for idiopathic pulmonary ﬁbrosis 77The subjects were those with severity degree I or II (PaO2
more than 70 Torr when resting; SpO2 more than 90% after
6-min walking test) for the NAC inhalation therapy test.Clinical trial of pirfenidone
Based on the results of an unblinded open label trial of
pirfenidone in the US,16 a phase II clinical trial was carried
out in Japan starting in December 2000.17 Based on the
diagnostic criteria at that time, 107 adults with ‘‘chronic
idiopathic interstitial pneumonia’’ (IPF, under current
diagnostic criteria) were studied (72 in the pirfenidone
group, 35 in the placebo group). This study differed from the
American clinical trial in that subjects were not advanced
cases of IPF, and those on immunosuppressive drugs or
steroids in excess of 10mg/day PSL equivalent units were
excluded. In addition, to more sensitively and critically
assess improvements in dyspnea during exertion, a unique
evaluation method showing blood oxygen saturation level
(minimum SpO2) improvement after 6min of constant speed
treadmill walking test was employed. The conventional
‘‘6-min walking test’’ is highly effort-dependent. Because
walking speed and walking distance change independently
as respiratory function improves, it has been difﬁcult toassess this efﬁcacy outcome before and after therapy.
However, the constant speed exercise tolerance evaluation
should be able to more objectively reﬂect oxygen consump-
tion for the same task volume. The remaining evaluation
indicators analyzed were the same as those in the American
clinical trial, but secondary endpoints were added. These
were the interstitial pneumonia markers KL-6 and SP-D,
often used in Japan, and acute exacerbation incidence,18
which is frequently recognized in reports from Japan.
After 6 months, the interim analysis reported ﬁve cases of
acute exacerbation out of 107 (4.5%), and as all cases were
skewed toward the placebo group (14.3%), based on the
efﬁcacy safety evaluation committee’s report, the results
were broken 9 months after the start of the trial and analysis
was conducted.
For cases in which the main endpoint was completion of
the 6-min constant speed walking test, the results showed a
signiﬁcantly higher degree of progression prevention for the
pirfenidone group as compared to the placebo group, with
better minimum SpO2 during the 6-min walking test both
6 and 9 months after starting administration. Further, after
6 months the minimum SpO2 during the 6-min walking test
showed signiﬁcant correlation with the SpO2 dropping area
(Figure 2), with signiﬁcant improvement shown by the
pirfenidone group as compared to the placebo group.
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Figure 2 The minimum SpO2 during the 6-minute walking test
showed signiﬁcant correlation with the SpO2 dropping area.
17
A. Azuma, J. Usuki78With regard to secondary endpoints, in terms of changes
in respiratory function test values, VC and TLC deterioration
were signiﬁcantly prevented in the pirfenidone group as
compared to the placebo group both 6 and 9 months after
starting administration. However, no signiﬁcant differences
were observed between the two groups for PaO2 changes
when resting, and serum KL-6 or SP-D marker value changes.
Meanwhile, although image analysis did not show the
reduction or disappearance of honeycomb lung, in some
cases in the pirfenidone group, the ground-glass appearance
of the lung parenchyma was reduced, suggesting that
pirfenidone may have an inhibiting effect on the early
ﬁbrotic stage. This was also felt to be the reason for the
inhibition of exercise endurance decline.
The same as in the clinical trials conduced in the US,
adverse events associated with pirfenidone administration
included photosensitivity (49.3%) and digestive complaints
(lack of appetite: 27.4%, gastric discomfort: 23.3%, nausea:
21.9%). However, all of these were dosage-dependent, and
temporary cessation or dose reduction enabled the trial to
be continued. Photosensitivity was seen in about half the
cases, which highlighted the importance of advising pirfe-
nidone patients to take sufﬁcient care with regard to
daylight exposure.
The same as the US clinical trials, the results of the phase
II clinical trial carried out in Japan showed that respiratory
function deterioration was inhibited, and further the
frequency of acute exacerbation was reduced.
Based on these results, a phase III clinical trial was carried
out with three groups. A total of 275 patients were randomly
assigned to high-dose (1800mg/day) of pirfenidone group
(H), low dose (1200mg/day) of pirfenidone group (L), and
the placebo group (P) (H:L:P ¼ 2:1:2).19 The main endpoint
was VC changes, and a key secondary endpoints progression
free survival interval (deﬁnition of progression: death or 10%
or greater drop in VC). Of 275 patients, 267 were included in
the full analysis set (108 assigned to Group H, 55 to Group L,
and 104 to Group P). Pirfenidone signiﬁcantly affected the
change in VC; at week 52, the difference in the adjusted
mean change in VC from baseline between Group H and P
was 0.07 l (p ¼ 0.0416). Pirfenidone signiﬁcantly affected
the secondary endpoint of progression free survival: the
difference between Groups H and P was statisticallysigniﬁcant (p ¼ 0.0280, Log-rank test). The most common
adverse events reported in patients treated with pirfeni-
done were photosensitivity in the skin and appetite loss. No
signiﬁcant difference in the serious adverse events was
noted among three groups. The phase II and phase III studies
demonstrated that pirfenidone therapy stabilized lung
function and improved progression free survival in patients
with IPF. With the safety and tolerability established, we
conclude that pirfenidone therapy is useful for treating
patients with IPF.Beneﬁcial role of PMX hemoperfusion therapy for
acute exacerbation of IPF
Acute exacerbation of IPF is a pathology with an extremely
adverse prognosis and produces acute respiratory failure
during the course of IPF. Activated neutrophilic inﬂamma-
tion damages the lung tissue, pathologically showing diffuse
alveolar damage, and the fatality ratio is said to be as high
as 80%. In recent years, global attention has focused on
acute exacerbation of IPF,20 with many reports thus far from
Japan,21 suggesting that the frequency differs according to
race.18
When the authors experimented with polymixicin (PMX)
adsorption therapy on IPF-AE patients, for whom improve-
ment was not seen with steroid pulse and immune
suppression therapies, improvement was veriﬁed for A-
aDO2, and in some cases patients succeeded in coming off
the respirator.22 Originally the PMX column was widely used
clinically for the purpose of endotoxin adsorption.23 After
the experience with these cases, PMX adsorption therapy
was carried out on ﬁve cases of steroid pulse- and immune
suppression-resistant acute exacerbation of IIPs. In four
cases, success was achieved in the area of respiratory
failure, and temporary improvement in A-aDO2 was veriﬁed
in two cases.4 In all of these cases, serum endotoxins were
negative, images showed inﬁltrative shadows with sclerotic
images in both lungs as the main and most of those with P/F
ratio of 300 or less manifested acute respiratory failure.
Adsorption of activated neutrophils might be a possible
mechanism of the column in the promising therapy for
exacerbation of IPF.Recent trends in IPF clinical studies
As mentioned at the beginning, the world is moving toward
large-scale, multicenter (including multiple countries) in IPF
clinical studies. Nonetheless, several issues remain to be
overcome. The main issues are those of ‘‘diagnostic
accuracy’’ and ‘‘disease diversity’’. IPF is one of the
pathological categories of IIPs, but there is a diversity of
life expentancy even within the same pathomorphology
disease category.
Even actual comparison of UIP and NSIP shows a poor life
prognosis for cases with DLco deterioration for each
pathomorphology.24 Also, it is clear that IPF cases with
pulmonary hypertension complication have a poorer life
prognosis than uncomplicated cases.25 In either case, the
existence of prognostic factors that cannot be determined
by pathomorphology alone is suggested.
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Figure 3 IPF clinical course. Reduction in living activity
accelerates as the disease progresses. Precipitous deterioration
may also occur in AE-IPF. A variety of prognostic factors are
involved, including inﬂammation, oxidative stress, pulmonary
hypertension (PAH), and progression of microvascular coagula-
tion. Composite parameters that can comprehensively evaluate
these prognostic factors are required.
Novel therapy for idiopathic pulmonary ﬁbrosis 79It is difﬁcult to judge statistical signiﬁcance without
carrying out analysis based on large-scale trials, but
variation arises due to sampling because of the rarity. There
is also the possibility of change in prognostic factors
between the initial and progressive stages.26 The second
issue is ‘‘validity of therapy evaluation indicators.’’
Complete recovery cannot be expected when the disease
progresses, and it can be analogized to the change in brunt
of therapy indicators, as when QOL evaluation was intro-
duced as a lung cancer therapy evaluation indicator.
Overall, the speed of decline in VC predicted is gradual in
the initial stages, but it becomes precipitous in the
progressive stages and the chance of acute exacerbation
also increases. Therefore, life prognosis also becomes
poorer. The results of clinical trials in recent years show
that VC and FVC percentages are much used as the best
prognostic indicators. However, as can be seen from the
results of massive dose NAC therapy, although a signiﬁcant
difference in FVC percentage was found as compared to the
placebo group, no improvement in life prognosis was seen.
This suggests that FVC percentage is not the only factor that
contributes to improvement in survival.
In pirfenidone clinical trials carried out in Japan, it is
thought that oxygen saturation minimum SpO2 during
exercise endurance reﬂects drug efﬁcacy, and plainly
indicates the relationship between pulmonary microcircula-
tion and oxygen consumption. As interstitial pneumonia and
pulmonary ﬁbrosis advance, the alteration in dynamic
structure results in the appearance of a remarkable effect
on pulmonary circulation resistance, retaining the possibility
of changing prognostic factors. This kind of change in
prognostic factors can occur for anyone as the disease
advances, but although pulmonary circulation resistance
may be an important prognostic factor from the initial
stages for some patients (IPF patients with pulmonary
hypertension complications), in some IPF patients it never
has an effect. Because factors that depend on the host and
external factors (environment, smoking, treatment, etc.)
are qualiﬁed separately, life prognosis is difﬁcult to assess
based only on pathological classiﬁcation and respiratory
function indicators in a resting state, and it was seen that
differences in minimum SpO2 during walking resulted in
noticeable differences in prognosis.27,28 In addition, even
for the same IPF, a high correlation was seen between
pulmonary hypertension and 6-min walking distance and
minimum SpO2, and the mortality ratio was signiﬁcantly high
in cases of pulmonary hypertension complications.25
Further, life prognosis differed markedly depending on
the existence of microthromboembolism (evaluated by
increased D-dimer).29
These prognostic factors present the necessity of analysis
as composite parameters in the future. In the same way as
the BODE index was presented for COPD, the authors believe
that it is necessary to introduce and develop useful
prognosis indicators for IPF.Prospects for the future
Until now, IIPs depended on pathological diagnosis classiﬁ-
cation. There is no question that IPF has the worst prognosis.
However, the prognosis even for the same IPF is affected bya variety of factors (Figure 3). Currently, VC or FVC
percentage is thought to be the most reliable prognosis
indicator. However, FVC percentage in interstitial pneumo-
nia complicated by the monogenic disease Hermansky–
Pudlak syndrome by no means continues the same type of
decrease.30 The indicators of secondary pulmonary hyper-
tension and pulmonary microcirculation are very much
implicated in ‘‘exercise endurance,’’ ﬁrst introduced in
pirfenidone clinical trials, and show the possibility of being
independent prognostic factors as the disease progresses.
Actually, regardless of image ﬁndings and lung capacity in a
resting state, the prognosis was extremely poor in cases of
reduced oxygen saturation while walking. Therefore, there
is a need for indicators that provide an overall link between
respiratory function and pulmonary circulation and gas
exchange, hitherto difﬁcult to evaluate, and prognosis
evaluation.
In fact, evaluating these indicators, not only at the time
of the initial pathological diagnosis, but as they change over
time, would appear to be most in line with clinical
classiﬁcation.
The efﬁcacy of interferon-g was indicated in the ﬁrst
small-scale clinical trials,4 but the results of a large-scale
trial with 330 subjects were judged negative, with no
signiﬁcant statistical difference in the primary endpoint.5
With the possibility of better therapeutic efﬁcacy in cases of
VC%455%, a further INSPIRE phase three clinical trial was
carried out with 826 IPF subjects having VC%455%. Once
again no signiﬁcant difference was obtained (Figure 4). From
this series of trial results, it became clear that the
expansion to large-scale trials completely overturned all
predictions. It is not clear at this point whether or not
unknown prognostic factors intervene and dilute the impact
of randomization as the scale of trials grows larger. As can
be seen from the walking trial analysis by Flaherty et al.26
the possibility that prognostic factors change with disease
stage must be borne in mind. In the progressive stage where
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Figure 4 Transition of interferon-g clinical trials. With the
introduction of large-scale trials, signiﬁcant difference in main
endpoint could no longer be obtained. What does this result
mean? It means that there is no treatment that can improve the
overall IPF prognosis. It is possible that factors inﬂuencing the
prognosis effected a disequilibrium in allocation in large-scale
trials. It is hoped that the analysis of effective cases will lead to
the evolution of order-made therapies.
A. Azuma, J. Usuki80VC percentage dropped, the prognosis can be computed by
focusing on 6-min walking distance, but the possibility that
multiple indicators may deﬁne the prognosis must be taken
into consideration in the non-progressive stage. The authors
consider that inﬂuential prognostic factors should at least be
seen as ‘‘allocated factors’’ for clinical trials. Then, while
there is room for development of therapeutic drugs relative
to each prognostic factor, intervention to prevent progres-
sion is important from an early stage.
At the present time in Japan, in addition to arterial blood
gas in a resting state, the higher ranked indicator used for
IIPs seriousness in Japan is SpO2 decrease (o90%) during
6-min walking. It would appear necessary to start with a
detailed evaluation of prognostic factors, go on to establish
validity and reproducibility of indicators, and then progress
to evaluate improvement in indicators for promising treat-
ment methods.
Currently, the possibility of IPF life prognosis improve-
ment is anticipated from the endothelin-1 inhibitor
(Bosentan) being promoted in Europe and the US, not only
through its inhibition of ﬁbrosis progression, but also
through its beneﬁcial effect on pulmonary hypertension.Summary
Drugs for the treatment of interstitial pneumonias continue
to be developed and tested yet none has yet proven to be
effective in the early stages of the disease. Outcome
measures for these studies may be able to use standard
imaging and pulmonary function techniques. However, once
the disease has moved to the progressive stages, a different
type of drug may be required to delay progression rather
than prevent initial ﬁbrosis. Outcome measures at that stage
may be different and may include survival duration, slower
progression in functional decline, and improved or main-
tained quality of life. These outcomes must be deﬁned a
priori so that comparable studies can be designed and
results combined in useful meta-analyses.CME Section
This article has been accredited for CME learning by the
European Board of Accreditation in Pneumology (EBAP). You
can receive 1 CME credit by successfully answering these
questions online.(a) Visit the journal CME site at http://www.resmedcme.-
com.(b) Complete the answers online, and receive your ﬁnal
score upon completion of the test.(c) Should you successfully complete the test, you may
download your accreditation certiﬁcate (subject to an
administrative charge).Educational questions
Answer the following questions:
1. What factors make it difﬁcult to study drugs for IPF?
a. Disease has several apparent subtypes
b. Patients all die before outcomes can be assessed
c. Pulmonary function results do not change
signiﬁcantly over time
d. The main outcomes are based on complex imaging
studies
e. Progression is very slow
2. There is a clear and widely agreed upon deﬁnition of IPF
True
False
3. The 6-min walk test is the only available test for
functional outcomes in clinical trials of people with
IPF?
True
False
4. It is important to develop standardized outcome measures
in clinical trials to facilitate:
a. Better funding opportunities
b. Meta-analysis opportunities
c. Opportunities for new equipment to be used
d. Better collaborative opportunities
e. 2 and 4
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